Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03777657 · ClinicalTrials.gov registry record · Phase 3
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
A Phase 3 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 3
- Development phase
- 997
- Enrollment target
NCT03777657 is a Phase 3 study that has completed, run by BeiGene. The registered enrollment target is 997 participants.
The verdict
NCT03777657, a Phase 3 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 997 participants
- Enrollment target
Study Summary
This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG Oxaliplatin
- DRUG Tislelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 997 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03777657
The ClinicalTrials.gov registry entry for NCT03777657 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 997 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03777657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03777657 about?
NCT03777657 is a clinical study titled "Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma". This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
What is the current status of trial NCT03777657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 997 participants. The study started on 2018-12-13. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT03777657?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Cisplatin (DRUG), Oxaliplatin (DRUG), Tislelizumab (DRUG).
Who is sponsoring clinical trial NCT03777657?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.